David A. Siegel Voyager Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 17,500 shares of VYGR stock, worth $138,425. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,500
Previous 15,300
14.38%
Holding current value
$138,425
Previous $129,000
25.58%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding VYGR
# of Institutions
134Shares Held
34.2MCall Options Held
35.3KPut Options Held
63K-
Armistice Capital, LLC New York, NY4.67MShares$37 Million0.59% of portfolio
-
Black Rock Inc. New York, NY4.4MShares$34.8 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.92MShares$31 Million1.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.23MShares$25.6 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.29MShares$18.1 Million0.1% of portfolio
About Voyager Therapeutics, Inc.
- Ticker VYGR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,647,600
- Market Cap $306M
- Description
- Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...